NASDAQ:VECT VectivBio (VECT) Stock Forecast, Price & News $16.55 0.00 (0.00%) (As of 06/1/2023 ET) Add Compare Share Share Today's Range$16.50▼$16.8050-Day Range$8.25▼$16.5552-Week Range$4.25▼$16.80Volume976,363 shsAverage Volume434,072 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice Target$24.33 ProfileProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media VectivBio MarketRank™ ForecastAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside47.0% Upside$24.33 Price TargetShort InterestHealthy2.09% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.22Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.80) to ($1.99) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.94 out of 5 stars 3.3 Analyst's Opinion Consensus RatingVectivBio has received a consensus rating of Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $24.33, VectivBio has a forecasted upside of 47.0% from its current price of $16.55.Amount of Analyst CoverageVectivBio has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.09% of the float of VectivBio has been sold short.Short Interest Ratio / Days to CoverVectivBio has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in VectivBio has recently increased by 123.45%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVectivBio does not currently pay a dividend.Dividend GrowthVectivBio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VECT. Previous Next 2.9 News and Social Media Coverage News SentimentVectivBio has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for VectivBio this week, compared to 1 article on an average week.Search Interest6 people have searched for VECT on MarketBeat in the last 30 days. MarketBeat Follows9 people have added VectivBio to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, VectivBio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.70% of the stock of VectivBio is held by insiders.Percentage Held by Institutions90.52% of the stock of VectivBio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for VectivBio are expected to decrease in the coming year, from ($1.80) to ($1.99) per share.Price to Book Value per Share RatioVectivBio has a P/B Ratio of 2.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About VectivBio (NASDAQ:VECT) StockVectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). The company was incorporated in 2019 and is headquartered in Basel, Switzerland.Read More Receive VECT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VectivBio and its competitors with MarketBeat's FREE daily newsletter. Email Address VECT Stock News HeadlinesMay 31, 2023 | benzinga.comMoore Kuehn Encourages VECT, EMBK, BACK, and RADI Investors to Contact Law FirmMay 28, 2023 | americanbankingnews.comVectivBio (NASDAQ:VECT) & Kodiak Sciences (NASDAQ:KOD) Financial ReviewJune 1, 2023 | Behind the Markets (Ad)[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software"The Washington Post Reports it's: "A revolution in warfare." The Sunday Times Reports it's: "a revolutionary power." Early investors can reap 5,633% gains as England, Germany, Japan and Australia rush to sign contracts. Get the name of the stock here >>>May 25, 2023 | businesswire.comVECTIVBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of VectivBio Holding AG ...May 25, 2023 | americanbankingnews.comVectivBio (NASDAQ:VECT) Cut to "Neutral" at Credit Suisse GroupMay 24, 2023 | msn.comPiper Sandler Downgrades VectivBio Holding (VECT)May 23, 2023 | markets.businessinsider.comWhat 4 Analyst Ratings Have To Say About VectivBio HoldingMay 23, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Rocket Pharmaceuticals (RCKT) and VectivBio Holding (VECT)June 1, 2023 | Behind the Markets (Ad)[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software"The Washington Post Reports it's: "A revolution in warfare." The Sunday Times Reports it's: "a revolutionary power." Early investors can reap 5,633% gains as England, Germany, Japan and Australia rush to sign contracts. Get the name of the stock here >>>May 23, 2023 | finance.yahoo.comIronwood (IRWD) to Acquire VectivBio for $1B, Stock Up 3.6%May 23, 2023 | msn.comCredit Suisse Downgrades VectivBio Holding (VECT)May 23, 2023 | msn.comSVB Leerink Downgrades VectivBio Holding (VECT)May 23, 2023 | americanbankingnews.comVectivBio (NASDAQ:VECT) Rating Lowered to Market Perform at SVB SecuritiesMay 23, 2023 | msn.comIronwood bulks up on digestive therapies with $1.15 billion VectivBio buyMay 22, 2023 | finance.yahoo.comVectivBio Stock Catapults 39% After Ironwood Agrees To Buy It For $1 BillionMay 22, 2023 | benzinga.comThinking about buying stock in Palantir Technologies, DraftKings, Micron Technology, Rain Oncology, or VectivBio?May 22, 2023 | finance.yahoo.comVectivBio Stock Catapults 38% After Ironwood Agrees To Buy It For $1 BillionMay 22, 2023 | finance.yahoo.comWhy Shares of VectivBio Holding Are Up TodayMay 22, 2023 | news.yahoo.comIronwood Pharma to acquire VectivBio for $1.15 billionMay 22, 2023 | msn.comIronwood Pharmaceuticals to acquire Swiss biotech VectivBio in deal valued at about $1 billionMay 22, 2023 | markets.businessinsider.comIronwood Pharma To Acquire VectivBio For $17/Shr In All-cash DealMay 11, 2023 | americanbankingnews.comVectivBio Holding AG (NASDAQ:VECT) Short Interest UpdateMay 10, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and VectivBio Holding (VECT)May 10, 2023 | markets.businessinsider.comPiper Sandler Keeps Their Buy Rating on VectivBio Holding (VECT)April 25, 2023 | americanbankingnews.comSVB Leerink Analysts Lift Earnings Estimates for VectivBio Holding AG (NASDAQ:VECT)April 24, 2023 | americanbankingnews.comPiper Sandler Increases VectivBio (NASDAQ:VECT) Price Target to $25.00April 22, 2023 | marketwatch.comShort Bowel Syndrome Market Forecast [2023-2030] | Top Key-Players in the Industry are - Merck KGaA, VectivBio AG, Ardelyx, OxTheraSee More Headlines VECT Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VECT Company Calendar Today6/01/2023Next Earnings (Estimated)7/19/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VECT CUSIPN/A CIK1836379 Webvectivbio.com Phone41-61-551-3030FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Forecast$24.33 High Stock Price Forecast$30.00 Low Stock Price Forecast$18.00 Forecasted Upside/Downside+47.0%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.05 Current Ratio9.14 Quick Ratio9.14 Sales & Book Value Annual Sales$27.34 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.27 per share Price / Book2.64Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta0.10 Key ExecutivesDr. Luca Santarelli M.D. (Age 53)Founder, CEO & Director Ms. Claudia D'Augusta Ph.D. (Age 52)Chief Financial Officer Dr. Christian Meyer M.D. (Age 55)Ph.D., Chief Operating Officer Dr. Alain Bernard Ph.D. (Age 65)Chief Technology Officer Mr. Patrick MalloySr. VP of Investor Relations & Strategic CommunicationsMr. Scott Applebaum (Age 55)Chief Legal Officer & Corp. Sec. Mr. Michael SteiningerSr. VP & Head of HRMr. Kevin Harris M.B.A. (Age 51)Chief Commercial Officer Dr. Sarah Holland Ph.D. (Age 59)Chief Bus. Officer Dr. Omar Khwaja M.D. (Age 51)Ph.D., Chief Medical Officer More ExecutivesKey CompetitorsAlvotechNYSE:ALVO111NASDAQ:YIAclarionNASDAQ:ACONWAinosNASDAQ:AIMDWAlpha Tau MedicalNASDAQ:DRTSWView All CompetitorsInstitutional OwnershipBalyasny Asset Management L.P.Sold 20,866 shares on 5/16/2023Ownership: 0.948%Gilder Gagnon Howe & Co. LLCBought 56,137 shares on 5/16/2023Ownership: 0.165%Geode Capital Management LLCBought 1,593 shares on 5/16/2023Ownership: 0.072%UBS Group AGSold 197,757 shares on 5/12/2023Ownership: 0.165%Bank of America Corp DEBought 35,353 shares on 5/12/2023Ownership: 0.117%View All Institutional Transactions VECT Stock - Frequently Asked Questions Should I buy or sell VectivBio stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for VectivBio in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VECT shares. View VECT analyst ratings or view top-rated stocks. What is VectivBio's stock price forecast for 2023? 5 equities research analysts have issued 12-month target prices for VectivBio's stock. Their VECT share price forecasts range from $18.00 to $30.00. On average, they expect the company's share price to reach $24.33 in the next year. This suggests a possible upside of 47.0% from the stock's current price. View analysts price targets for VECT or view top-rated stocks among Wall Street analysts. How have VECT shares performed in 2023? VectivBio's stock was trading at $8.6650 on January 1st, 2023. Since then, VECT stock has increased by 91.0% and is now trading at $16.55. View the best growth stocks for 2023 here. Are investors shorting VectivBio? VectivBio saw a increase in short interest in May. As of May 15th, there was short interest totaling 580,300 shares, an increase of 123.5% from the April 30th total of 259,700 shares. Based on an average daily trading volume, of 574,800 shares, the short-interest ratio is currently 1.0 days. Approximately 2.1% of the company's stock are sold short. View VectivBio's Short Interest. When is VectivBio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 19th 2023. View our VECT earnings forecast. When did VectivBio IPO? (VECT) raised $128 million in an initial public offering on Friday, April 9th 2021. The company issued 7,500,000 shares at $16.00-$18.00 per share. BofA Securities, SVB Leerink and Credit Suisse served as the underwriters for the IPO and LifeSci Capital was co-manager. What is VectivBio's stock symbol? VectivBio trades on the NASDAQ under the ticker symbol "VECT." Who are VectivBio's major shareholders? VectivBio's stock is owned by many different institutional and retail investors. Top institutional investors include CHI Advisors LLC (0.00%), Tekla Capital Management LLC (0.00%), Balyasny Asset Management L.P. (0.95%), Gilder Gagnon Howe & Co. LLC (0.17%), UBS Group AG (0.16%) and Bank of America Corp DE (0.12%). How do I buy shares of VectivBio? Shares of VECT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is VectivBio's stock price today? One share of VECT stock can currently be purchased for approximately $16.55. How can I contact VectivBio? The official website for the company is vectivbio.com. The company can be reached via phone at 41-61-551-3030 or via email at ir@vectivbio.com. This page (NASDAQ:VECT) was last updated on 6/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VectivBio Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.